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SLC15A4 is a lysosome-resident, proton-coupled
amino-acid transporter that moves histidine and oli-
gopeptides from inside the lysosome to the cytosol
of eukaryotic cells. SLC15A4 is required for Toll-like
receptor 7 (TLR7)- and TLR9-mediated type I inter-
feron (IFN-I) productions in plasmacytoid dendritic
cells (pDCs) and is involved in the pathogenesis of
certain diseases including lupus-like autoimmunity.
How SLC15A4 contributes to diseases is largely un-
known. Here we have shown that B cell SLC15A4
was crucial for TLR7-triggered IFN-I and auto-
antibody productions in a mouse lupus model.
SLC15A4 loss disturbed the endolysosomal pH regu-
lation and probably the v-ATPase integrity, and these
changes were associated with disruption of the
mTOR pathway, leading to failure of the IFN regulato-
ry factor 7 (IRF7)-IFN-I regulatory circuit. Importantly,
SLC15A4’s transporter activity was necessary for the
TLR-triggered cytokine production. Our findings re-
vealed that SLC15A4-mediated optimization of the
endolysosomal state is integral to a TLR7-triggered,
mTOR-dependent IRF7-IFN-I circuit that leads to
autoantibody production.
INTRODUCTION
Solute carrier family (SLC) 15A4, a resident lysosomal proton-
coupled histidine or oligopeptide transporter, is preferentially ex-
pressed in immune cells, including dendritic cells (DCs) and B
cells (Blasius et al., 2010; Sasawatari et al., 2011; Yamashita
et al., 1997). SLC15A4 has 12 membrane-spanning regionsImand transports certain types of amino acids, particularly histi-
dine, and oligopeptides such as nucleotide oligomerization
domain-1 (NOD1) ligand, L-Ala-g-D-Glu-meso-diaminopimelic
Acid (tri-DAP), and carnosine, together with a proton (Sasawatari
et al., 2011; Yamashita et al., 1997). Its transporter activity is pH-
dependent (Yamashita et al., 1997), and thus is maximized in the
acidic lysosomal environment. SLC15A4 is crucial for inflamma-
tory responses triggered by Toll-like receptor 7 (TLR7), TLR9,
and NOD1 (Blasius et al., 2010; Sasawatari et al., 2011). A
disruption in the SLC15A4 gene impairs TLR7- and TLR9-
triggered interferon (IFN)-b productions in plasmacytoid DCs
(pDCs) and ameliorates colitis in mice (Blasius et al., 2010; Sasa-
watari et al., 2011). This SLC15A4-dependent pDC function
contributes to the pathogenesis of lupus-like disease (Baccala
et al., 2013). Genome-wide analyses show that SLC15A4 is
closely associated with inflammatory diseases such as type 2
diabetes (Takeuchi et al., 2008), systemic lupus erythematosus
(SLE) (Han et al., 2009; He et al., 2010; Wang et al., 2012), and
inflammatory bowel disease (IBD) (Lee et al., 2009). These obser-
vations indicate that SLC15A4 might be a key regulator in auto-
immune diseases. However, how SLC15A4 contributes to TLR
signaling and the disease pathogenesis is unclear.
SLE is a systemic autoimmune disease accompanied by auto-
antibody production, particularly anti-DNA and anti-small nuclear
ribonucleoprotein (snRNP) antibodies, with resultant tissue dam-
age (Liu and Davidson, 2012; Mortensen et al., 2008). Type-1
interferon (IFN-I) is important in the pathogenesis of SLE, in which
it provokes a breakdown in peripheral tolerance through DC acti-
vation (Banchereau and Pascual, 2006; Preble et al., 1982). Nu-
cleic acid-sensing TLRs such as TLR7 and TLR9 are pivotal in
SLE by triggering IFN-I production by pDCs and by activating au-
toreactive B cells (Christensen et al., 2006; Green and Marshak-
Rothstein, 2011; Marshak-Rothstein, 2006). TLR7 and the type-
1 interferon, IFN-a also act together to generate autoantibodies
by promoting a class switch to pathogenic immunoglobulin G2a
(IgG2a) and IgG2c isotypes (Heer et al., 2007;Marshak-Rothstein,munity 41, 375–388, September 18, 2014 ª2014 Elsevier Inc. 375
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pathogenesis of SLE, understanding pathways that regulate the
TLR7-IFN-a-autoantibody production is important for the devel-
opment of therapeutics to block the autoimmune response.
Endolysosomal systems are important for signaling events
that manage cellular activities, such as energy metabolism, sur-
vival, and pathogen defense (Kim et al., 2008; Mancuso et al.,
2009; Settembre et al., 2013). In immune cells, recruitment of
TLR7 and TLR9 to endolysosomes is crucial for the recognition
of nucleic acids (Kim et al., 2008; Mancuso et al., 2009) and
the production of an IFN-I response; in this process, limited pro-
teolysis of these TLRs, mediated by lysosomal proteases such
as cathepsins, is required for efficient ligand recognition (Ewald
et al., 2008; Onji et al., 2013; Park et al., 2008). Upon receptor
engagement, the NF-kB pathway is activated through an
adaptor protein MyD88-IRAK4 pathway, and in parallel, the
IFN-I response is activated through the MyD88-interferon
regulatory factor-7 (IRF7) pathway (Kawai and Akira, 2010),
which requires mammalian target of rapamycin (mTOR) activity
(Cao et al., 2008). Rapamycin treatment or the introduction of
an inactive form of mTOR blocks IRF7’s association with the
MyD88-signaling complex and its subsequent phosphoryla-
tion-dependent nuclear translocation, thereby inhibiting IFN-I
transcription (Cao et al., 2008; Schmitz et al., 2008).
Here we focused on SLC15A4’s functional role in the patho-
genesis of lupus-like disease, particularly in autoantibody
production. We found that SLC15A4 was required for the
mTOR-dependent IFN-I response to TLR7 stimulation. Our re-
sults show that SLC15A4 plays a fundamental role in optimizing
the lysosomal environment for efficient inflammatory signaling
and autoantibody production.
RESULTS
Selective Impairment of IgG2a and IgG2c Productions in
Slc15a4–/– Mice
We first examined serum immunoglobulin concentrations in
C57BL/6 Slc15a4/mice. The naive Slc15a4/ mice had
reduced concentrations of IgG2c antibodies, a key isotype for
antibody-mediated effector functions (Figure 1A); IgA concentra-
tions were also decreased, but only slightly. Other isotypes were
not affected (see Figure S1A available online). The defective
IgG2c production in Slc15a4/mice was intrinsic to B cells (Fig-
ures 1B and S1B). The OVA-specific IgG2a (functionally identical
to IgG2c of C57BL/6) in BALB/c Slc15a4/ mice was also
severely defective, but the IgM production after OVA immuniza-
tion was not (Figure 1C). The bone-marrow (BM) and spleen B
cell populations, follicular structure in the spleen, and BCR-
dependent activation machinery appeared normal in theFigure 1. SLC15A4 Is Required for IgG2a and IgG2c Autoantibody Prod
(A and B) Serum IgG2c in naiveWT or Slc15a4/mice (A) or in B cell-deficient mic
Figures S1A and S1B for other isotypes. **p < 0.01; *p < 0.05.
(C) Antigen-specific antibody production. Horizontal bars and error bars show th
(D) Presence of anti-snRNP or anti-dsDNA antibodies in sera from tetramethylpent
point represents the value from one mouse; horizontal bars and error bars show
(E and F) BM cells were reconstituted with WT or Slc15a4/ cells mixed with cel
values in sera were evaluated by ELISA 5 months after TMPD treatment.
(G and H) Slc15a4+/ or Slc15a4/ littermates on a Faslpr/lpr background were
Anti-dsDNA or anti-snRNP antibody values in sera were evaluated by ELISA. *p
ImSlc15a4/ mice (Figures S1C–S1E). These results indicated
that SLC15A4 is important for IgG2a and IgG2c productions
and that this contribution is B cell intrinsic.
SLC15A4 Is Required in B Cells for Autoantibody
Production in Experimental Mouse Lupus
We next asked whether SLC15A4 plays a role in autoantibody
production, because SLC15A4 is implicated in the pathogenesis
of human SLE (Han et al., 2009; He et al., 2010; Wang et al.,
2012).We used amousemodel with a lupus-like disease induced
by 2,6,10,14-tetramethylpentadecane (TMPD; also known as
pristane) (Lee et al., 2008). Twenty weeks after TMPD treatment,
anti-snRNP or anti-dsDNA IgG antibodies were elevated in the
sera of the WT, but not the Slc15a4/ mice (Figure 1D). Patho-
genic IgG2a autoantibody values were also reduced in the
Slc15a4/ mice (Figure 1D, right). The presence of antinuclear
antibodies in sera was confirmed by immunostaining (Fig-
ure S1F). There was no significant difference in spleen weight
or lymphocyte subsets between the Slc15a4/ andWTmice af-
ter TMPD treatment (Figures S1G and S1H). TMPD treatment
alone did not elevate the blood urea nitrogen (BUN) concentra-
tions, as reported previously (Lee et al., 2008) (Figure S1I).
To determine whether the lack of SLC15A4 in B cells was
solely responsible for the reduced antinuclear antibody produc-
tion in the Slc15a4/ mice, we generated BM chimera mice by
transplanting both Ighm/ (mMT) BM cells and Slc15a4/ BM
cells into C57BL/6 mice. The SLC15A4 deficiency was restricted
to B cells in the resultant BM chimera mice. The lack of SLC15A4
in B cells reduced the production of anti-snRNP and anti-DNA
antibodies after TMPD treatment (Figures 1E and 1F), indicating
that SLC15A4 in B cells is crucial for TMPD-triggered autoanti-
body production. SLC15A4’s importance in autoimmune onset
was further demonstrated with lupus-prone C57BL/6lpr/lpr
mice, which develop an autoantibody profile similar to that of
SLE patients. Slc15a4/mice on the C57BL/6lpr/lpr background
showed ameliorations of splenomegaly (Figures 1G) and of anti-
nuclear IgG2c antibody productions (Figure 1H).
Slc15a4–/– B Cells Display Defective Effector Functions
Because TLR7 and TLR9 are crucial for the pathogenesis of
TMPD-induced lupus-like diseases (Christensen et al., 2006;
Green and Marshak-Rothstein, 2011), and TLR7 is pivotal for
IgG2c antibody production (Figure S2A), we evaluated the B
cells’ ability to produce antibodies upon TLR stimulation.
Slc15a4/ B cells completely failed to produce IgG2c, while still
secreting the same amount of IgM asWTB cells (Figure 2A), indi-
cating that the IgG2c production strictly depends on SLC15A4
function. The inductions of g2a germline transcription (GLT)
and Tbx21 (encoding T-bet), whose transcription is induced byuction
e reconstituted withWT or Slc15a4/B cells (B) was quantified by ELISA. See
e mean and SD from four mice. *p < 0.05. n.s., not significant.
adecane (TMPD)-treatedWT andSlc15a4/mice, determined by ELISA. Each
the mean and SD. **p < 0.01, *p < 0.05.
ls from B cell-deficient mMT mice. Anti-snRNP (E) and anti-dsDNA (F) antibody
analyzed for autoimmune phenotypes at 18 weeks old. (G) Spleen weight. (H)
< 0.05. See also Figure S1.
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Figure 2. SLC15A4 Is Selectively Required for TLR7 and TLR9 Responses in B Cells
(A) In vitro immunoglobulin secretion fromWT or Slc15a4/ B cells stimulated with TLR ligands for 6 days. IgM and IgG2c in culture supernatant were quantified
by ELISA. Bars represent the average of triplicates and SD. **p < 0.01.
(B) IL-6 secretion from WT or Slc15a4/ B cells stimulated with TLR ligands for 48 hr was measured by ELISA. **p < 0.01.
(C) Quantitative RT-PCR analysis of Tnf or Ifnb1 transcripts in B cells stimulated with TLR ligands. Expression was normalized to Hprt (hypoxanthine-guanine
phosphoribosyl transferase). Results are representative of four independent experiments.
(legend continued on next page)
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SLC15A4 Links mTOR and IRF7-IFN-I CircuitStat1 in cooperation with Ets1 (Nguyen et al., 2012; Peng et al.,
2002) and is required for the g2aGLT (Xu and Zhang, 2005), were
selectively and severely impaired in Slc15a4/ B cells following
TLR7 or TLR9 stimulation (Figure S2B). TLR agonists induced
Aicda (encoding Activation-induced cytidine Deaminase; AID)
transcription in both Slc15a4/ and WT B cells (Figure S2B),
suggesting that the absence of SLC15A4 does not induce de-
fects in the switching machinery itself. The transcriptional Tlr4,
Tlr7, and Tlr9 expressions were equivalent in Slc15a4/ and
WT B cells (Figure S2C).
We next examined the TLR-triggered cytokine production by B
cells and found that Slc15a4/ B cells produced markedly less
IL-6 upon TLR7 or TLR9 stimulation (Figure 2B). The transcrip-
tional inductions of Tnf and Ifnb1 were also severely impaired in
Slc15a4/ B cells stimulated with TLR7 or TLR9 ligand (Fig-
ure 2C). The TLR4-dependent induction of Ifnb1 transcripts
was also decreased in Slc15a4/ B cells, although the IL-6
secretion (Figure 2B) and Tnf transcripts (Figure 2C) in the
Slc15a4/ B cells were equivalent to those of WT B cells. This
seems reasonable, because in the TLR4 pathway, IL-6 and
TNF-a are produced in response to TIRAP-MyD88-dependent
signaling at the cell surface, whereas IFN-b signaling is mediated
by a TRIF-TRAM-dependent event at the endolysosomes (Kagan
et al., 2008), and SLC15A4 affected only the latter. The impaired
IFN-b production in Slc15a4/ B cells was confirmed by the
observation that Stat1 phosphorylation, which is induced by
IFN-I’s binding to IFNAR in an autocrine and/or paracrinemanner,
decreased markedly in Slc15a4/B cells treated with R837
(TLR7 agonist) or CpG (Figure 2D). Adding IFN-I provoked
Stat1 phosphorylation in Slc15a4/ B cells, indicating that
the IFNAR-proximal signaling itself is not influenced by the
SLC15A4 loss (Figure S2D). IFN-I also partially, but not
completely, rescued the Slc15a4/ B cells’ secretion of IgG2c
(Figure 2E). TLR-triggered IkBa phosphorylationwas not affected
inSlc15a4/B cells (Figure 2D). Analysis of the B cell maturation
and proliferation by the induction of CD86 and decrease in CFSE
fluorescence intensity, respectively, showed that the maturation
and proliferation defects of the Slc15a4/ B cells were only
noticeable when the cells were stimulated with R837 (Figure 2F).
These results suggest that various TLR-signaling events depend
on SLC15A4 to different degrees. They also suggest that the pro-
liferative defect in Slc15a4/ B cells is not a direct cause of the
defective pathogenic antibody production, because CpG- or
LPS-stimulation did not promote IgG2c secretion in Slc15a4/
B cells under proliferative conditions. From these results, we
conclude that the B cell-intrinsic defect in pathogenic antibody
production in Slc15a4/ mice is partly due to the impaired pro-
duction of IFN-I upon TLR stimulation.
Crucial Role of SLC15A4 in Establishing the IRF7-IFN-I
Regulatory Circuit
Wenext investigated themechanism for SLC15A4’s involvement
in TLR-triggered IFN-I production. IRF7 is the most prominent(D) WT or Slc15a4/ B cells were stimulated with TLR ligands for the indicated
(E) WT or Slc15a4/ B cells were stimulated with R837 alone or R837 and recom
was quantified by ELISA. Results are representative of three independent experi
(F) CD86 expressed onWT or Slc15a4/B cells 24 hr after TLR stimulation was d
stimulation by flow cytometry. See also Figure S2.
Imtranscription factor that induces IFN-I downstream of the
TLR7-MyD88 pathway (Honda et al., 2005; Kawai et al., 2004).
Because Irf7/ B cells showed severely impaired IgG2c, but
not IgM production (Figures 3A and 3B), we hypothesized that
an impaired regulation of IRF7 in Slc15a4/ B cells caused
the defective IFN-I production and the resulting IgG2c produc-
tion. RT-PCR analyses showed that steady-state B cells con-
tained detectable Irf7 transcripts at similar amounts in WT and
Slc15a4/ B cells (Figure 3C). The steady-state Irf7 transcrip-
tion was decreased in Ifnar1/ B cells, suggesting that IRF7’s
expression is controlled by IFN-I signaling, even in the steady
state. R837 treatment induced Irf7 transcription in WT B cells,
but not in Slc15a4/ B cells (Figure 3D). This finding indicated
that the TLR7-mediated transcriptional regulation of IRF7 de-
pends on SLC15A4. This suppression was rescued by adding
exogenous IFN-a (Figure 3E). The Irf7 transcript induction was
also impaired in Ifnar1/B cells stimulated with R837, as ex-
pected (Figure 3D). These results together indicate that the
defective Irf7 transcription induction observed in Slc15a4/ B
cells results from the loss of SLC15A4-dependent IFN-I produc-
tion upon TLR stimulation. The induction of IRF7 transcription
downstream of TLR9 was also impaired in the Slc15a4/ or
Ifnar1/ B cells (Figure 3D). In contrast, TLR4-dependent IRF7
expression was somehow dependent on IFN-I but independent
of SLC15A4 (Figure 3D). Thus, SLC15A4 is required for the
IFN-I-dependent transcriptional regulation of IRF7 that is
controlled by the IFNAR signaling pathway.
We further verified the IRF7 protein expression inSlc15a4/B
cells. IRF7 protein was increased in WT B cells after R837 stim-
ulation, and IFN-a treatment further enhanced its expression
(Figure 3F). R837 stimulation did not increase the IRF7 protein
expression in Ifnar1/Bcells, nor did additional IFN-a treatment
(Figure 3F). R837 also failed to increase IRF7 protein expression
in Slc15a4/ B cells, consistent with the PCR data (Figure 3F).
The addition of exogenous IFN-a did not rescue the IRF7 protein
expression in Slc15a4/ B cells (Figure 3F), even though it
almost completely recovered the Irf7 transcription (Figure 3E).
Nuclear fractionation and immunoblot analyses confirmed the
reduced nuclear translocation of IRF7, but not IRF5, in
Slc15a4/ B cells (Figure 3G). Although B cell IRF5 is known
to contribute to autoantibody production in SLE-like disease (Sa-
vitsky et al., 2010; Xu et al., 2012), we found no observable defect
in IRF5 expression upon TLR stimulation (Figures S3). These ob-
servations indicate that SLC15A4 is involved in both the IFN-I-
dependent transcriptional regulation of IRF7 and its translational
regulation.
The Transporter Activity of SLC15A4 Is Important in
TLR7- or TLR9-Induced Responses
To obtain insight into how SLC15A4 functions in TLR7-triggered
B cell responses, we established a transporter activity-inacti-
vated SLC15A4 mutant (SLC15A4 E465K), in which glutamic
acid at 465 was replaced with lysine. This glutamic acid (withinperiods and analyzed by immunoblotting.
binant mouse IFN-a (500 U/ml) for 6 days, and IgG2c in the culture supernatant
ments.
etected by flow cytometry. CFSE fluorescence dilution was detected 72 hr after
munity 41, 375–388, September 18, 2014 ª2014 Elsevier Inc. 379
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Figure 3. Requirement of SLC15A4 for TLR7- or TLR9-Triggered IRF7 Induction
(A) In vitro immunoglobulin secretion from WT or Irf7/ B cells stimulated with TLR ligands for 6 days. IgM and IgG2c in culture supernatant were quantified by
ELISA. Bars represent the average of triplicates andSD. **p < 0.01. RT-PCRanalysis ofg1 org2agermline transcripts inR837-activated Irf7/Bcells is also shown.
(B) Serum concentrations of IgM and IgG2c in 7-week-old WT and Irf7/ mice were determined by ELISA. *p < 0.05.
(C and D) Quantitative RT-PCR analysis of Irf7 transcripts in naive WT, Slc15a4/, or Ifnar1/ B cells (C) or in the cells treated with TLR ligands for 24 hr (D).
(E) Quantitative RT-PCR analysis of Irf7 transcripts in R837-treated B cells in the presence or absence of IFN-a for 24 hr.
(F)WT,Slc15a4/, or Ifnar1/Bcellswere stimulatedwith reagents indicated for 24 hr andwere subjected to immunoblotting for IRF7.Grb2was used as a control.
(G) R837-induced IRF7 or IRF5 nuclear translocation inmouseWT,Slc15a4/, or Ifnar1/Bcells was analyzed by immunoblot. Rho and Lamin B1were controls
for the cytosolic and nuclear fractions, respectively. Relative immunoblot intensities of IRF7 normalized to Lamin B1 are indicated below each band.
(H) Irf7 mRNA expression in WT B cells stimulated with R837 combined with rapamycin (Rapa), Torin 1 (Torin), or IFN-a for 24 hr.
(I) Ramos B cells expressing human IRF7-GFP fusion protein were stimulated with R848 with or without rapamycin for 24 hr. Scale bars represent 10 mm. See also
Figure S3.
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which inactivates SLC15A1’s transporter activity (Xu et al.,
2009). SLC15A4 E465K was transcribed normally and localized
to the lysosomal membrane (Figures 4A and 4B), but lacked
transporter activity, given that tri-DAP-triggered NF-kB activa-
tion, which is completely dependent on Tri-DAP transport by
SLC15A4 (Sasawatari et al., 2011), was not rescued when
SLC15A4 E465K cDNA was introduced into SLC15A4-silenced
293T cells (Figures 4C and 4D). The expression of SLC15A4
E465K itself did not affect Flt3L-dependent DC differentiation
(Figure 4E). The introduction of SLC15A4 WT into Slc15a4/
BMDCs recovered the TLR7-induced transcription of Ifnb1 and
Il12b, but that of SLC15A4 E465K did not (Figure 4F). The
TLR7- and TLR9-dependent productions of IL-6 and TNF-a
were also not observed in SLC15A4 E465K-introduced BMDCs
(Figure 4G). Similarly, the transcriptional induction of Ifnb1 and
Irf7 in Slc15a4/ B cells were not recovered by the expression
of SLC15A4 E465K (Figures 4H and 4I). These data indicate
that SLC15A4’s transporter activity is important for the TLR7-
and TLR9-triggered cytokine productions and IRF7’s induction
upon TLR7 stimulation.
SLC15A4 Loss Causes Histidine Accumulation and
Impaired pH Regulation in Lysosomes
The above observations raised the possibility that the correctly
controlled flow of amino acids or protons from lysosomes into
the cytosol is important for efficient immune responses that
involve the endolysosome. Thus, we compared the amounts of
lysosomal histidine and the lysosomal pH between Slc15a4/
and WT B cells. The total intracellular histidine was comparable
between the Slc15a4/ and WT B cells (Figure 5A). However,
when lysosomal vesicles collected by density-gradient ultra-
centrifugation were analyzed, the amount of histidine but not
glutamine was increased in the fraction containing high amounts
of lysosomal-associated membrane protein-1 (LAMP1) and
LAMP2 (fraction #5) (Figure 5B). The majority of SLC15A4 was
also contained in fraction #5 with transfectants expressing hem-
agglutinin (HA)-tagged SLC15A4 (Figure S4A). Other cationic
amino acids such as lysine and arginine were slightly increased
in the Slc15a4/ fraction #5, but increase of histidine and hista-
mine was pronounced (Figure 5B). These findings suggested
that the loss of SLC15A4 causes a change in the amino acid envi-
ronment within the lysosomes, particularly in histidine, which is
its most potent substrate (Yamashita et al., 1997).
Histidine is a unique amino acid with an imidazole functional
group, which retains effective buffer capacity at physiological
pH. Therefore, we hypothesized that the histidine accumulation
within lysosomesmight affect the lysosomal pH. Flow cytometric
evaluation of the lysosomal acidity with Lysotracker indicated
that the loss of SLC15A4 resulted in impaired lysosomal acidifi-
cation upon R837 stimulation (Figure 5C). The uptake of TLR7
ligand was not different between the WT and Slc15a4/ B cells
(Figure 5D). Biochemical analyses showed that pro and mature
forms of cathepsin B were decreased in the Slc15a4/
compared with WT B cells (Figure S4B), although Slc15a4/
andWTB cells had similar mRNA amounts for the cathepsin (Fig-
ure S4C). Transmission electron microscopy did not reveal
obvious abnormalities in the morphology of the intracellular
vesicles in the Slc15a4/ B cells (Figure S4D). Interestingly,Imthe addition of exogenous histidine caused an aberrant pH
change in the lysosomes upon TLR7 stimulation (Figure 5E).
Thus, there appears to be an optimal range of histidine concen-
trations for proper control of the lysosomal pH. These results
suggest that SLC15A4’s regulation of histidine homeostasis is
a possible mechanism for maintaining the proper lysosomal pH.
SLC15A4 Loss Changes the Activities of V-ATPase
and mTOR
Vacuolar H+-ATPase (v-ATPase) is known to be responsible for
establishing the lysosomal proton gradient, in amanner requiring
its ATPase activity (Mindell, 2012). We next examined whether
the loss of SLC15A4 influenced the v-ATPase activity. We eval-
uated the ATPase activities in the lysosome-rich vesicular frac-
tion (equivalent to fraction #5 in Figure 5B) in the presence or
absence of bafilomycin A1, a selective inhibitor of v-ATPase ac-
tivity, and found that the sensitivity to bafilomycin A1 was signif-
icantly different between Slc15a4/- and WT-derived fractions
(Figure S4E). The v-ATPase consists of multicomponent V0
and V1 domains, and bafilomycin A1 is a noncompetitive inhibi-
tor that binds to the V0 domain and inhibits the V1 ATPase.
Because the protein amounts of v-ATPase components included
in the lysosome-rich fraction were not different between
Slc15a4/ andWTB cells (Figure S4E), the different bafilomycin
A1 sensitivity between the Slc15a4/ and WT-derived v-
ATPase implies that the Slc15a4/-derived v-ATPase complex
was structurally altered in the lysosomal membrane. Thus, in
addition to histidine’s buffering capacity, v-ATPase dysregula-
tion could contribute to the impaired acidification of the lyso-
somes in Slc15a4/ cells.
A recent study showed that lysosome-resident v-ATPase
senses amino acids inside the lysosome lumen and induces
RagGTPase activation, causing translocation of themTOR com-
plex to the lysosomal surface (Zoncu et al., 2011a). This close as-
sociation of v-ATPase function with mTORC1 activity raised the
possibility that SLC15A4 loss affects mTORC1. We therefore
examined the mTORC1 activation in Slc15a4/ B cells. IFN-I
activates the mTOR pathway and its translational activity, in
which 4E-BP1 is phosphorylated by p70S6 kinase (Lekmine
et al., 2003), thereby releasing 4E-BP1 from its function as a
repressor of protein translation. IFN-I-dependent 4E-BP1 phos-
phorylation was lower in Slc15a4/ than in WT B cells (Figures
6A and 6B and S5A). In addition, the phosphorylation on S2481
of mTOR, which is the autophosphorylation site associated with
mTORC1’s catalytic activity (Soliman et al., 2010), and phos-
phorylated p70S6 kinase, an mTORC1 downstream substrate,
were diminished in Slc15a4/ B cells (Figure 6A). These results
indicated that the translational repressor activity of 4E-BP1 was
retained as a consequence of SLC15A4 deficiency. The IFN-I-
induced Akt phosphorylation was detected in both WT and
Slc15a4/ B cells (Figure 6A). Impaired phosphorylation of
mTOR (Ser2481) and p70S6K (Thr389) in Slc15a4/ B cells
were observed before IFN-I stimulation. Immunohistochemical
analyses indicated that SLC15A4 and mTOR were colocalized
in the same LAMP1-positive compartments (Figure 6C). Exami-
nation of the distribution ofmTOR complexes by vesicle fraction-
ation revealed that the amount of Raptor in the LAMP1-contain-
ing fractionswas decreased in theSlc15a4/Bcells (Figures 6D
and S5B). Consistent with this observation, the amount of p62,munity 41, 375–388, September 18, 2014 ª2014 Elsevier Inc. 381
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SLC15A4 Links mTOR and IRF7-IFN-I Circuitwhich is required for mTORC1’s recruitment to the lysosome and
activation (Duran et al., 2011), was also decreased in the LAMP1-
containing fractions (Figure 6D). Because resting B cells have
scant cytoplasm and lysosomes, we confirmed the abnormal
distribution of Raptor in the absence of SLC15A4withmast cells,
which also express SLC15A4 and have well-developed lyso-
some-related vesicles (Figure S5C). The transcription of lyso-
some-associated genes including those involved in mTOR and
TFEB-dependent lysosomal biogenesis were not affected by
the lack of SLC15A4 (Figure S5D) (Settembre et al., 2013).
Collectively, these results indicate that SLC15A4 is necessary
for establishing a lysosomal state that guarantees the functional
integrity of the v-ATPase and mTORC1 complex.
Slc15a4–/– B Cells Display Impaired mTOR-Dependent
Translational Regulation of IRF7
We next asked how the dysregulated mTOR-pathway in
Slc15a4/ B cells was involved in the impaired TLR7 response.
As the mTOR-dependent phosphorylation of 4E-BP1 was sup-
pressed in Slc15a4/ B cells, 4E-BP1’s function as a repressor
of protein translation might be retained in these cells. Because
4E-BP1 can directly regulate the IRF7 protein translation (Colina
et al., 2008), we hypothesized that the SLC15A4-dependent
translational regulation of IRF7 shown in Figure 3 might be
accomplished in an mTOR-dependent fashion. To test this pos-
sibility, we investigated rapamycin’s effect on the IRF7 protein
expression. Rapamaycin completely abrogated the R837-
induced IRF7 protein expression in WT B cells (Figure 3F),
although mTOR inhibitors did not cause Irf7 mRNA loss (Fig-
ure 3H). This findingwas inconsistent with previous observations
in CpG-stimulated pDCs, that rapamycin inhibits IRF7’s phos-
phorylation but does not alter IRF7’s protein expression (Cao
et al., 2008).We confirmed that rapamycin inhibited the accumu-
lation of IRF7 in the nucleus uponR837 stimulation in B cells (Fig-
ure 3I). Rapamycin had less effect on the IRF7 protein amount
in Slc15a4/ B cells than in WT B cells (Figure 3F), suggesting
that control of the mTOR pathway-dependent translational re-
gulation of IRF7 depends on SLC15A4. Taken together, these
findings indicate that SLC15A4 is pivotal for promoting IRF7
translation by controlling the IFNAR-mTOR-4E-BP1 signaling
axis, which is responsible for establishing the IRF7-IFN-I regula-
tory circuit.
Contribution of the SLC15A4-mTOR Axis to
IFNa-Dependent g2a GLT Induction
Finally, to confirm mTOR’s involvement in pathogenic antibody
production, we used an mTOR-specific inhibitor, Torin 1.Figure 4. SLC15A4’s Transporter Activity Is Necessary for IFN-I Produ
(A and B) HA-tagged WT or the E465K mutant of human SLC15A4 expressed
microscopy (B). Scale bars represent 10 mm.
(C) HEK293T cells harboring an NF-kB luciferase reporter were stimulated with T
(D) SLC15A4-silenced HEK293T cells transfected with WT or E465K mutant huma
quantified by luciferase reporter assay.
(E–G) Reconstitution of human SLC15A4 E465Kmutant in HSC-derived dendritic c
DCs, and the transduction efficiency was confirmed by GFP expression. (F) Qu
consituted DCs stimulated with R837. Expression was normalized to Hprt. Res
reconstituted DCs were stimulated with R837 or CpG for 48 hr, and secreted cy
(H and I) Quantitation of Ifnb1 transcripts in WT- or E465K-reconstituted B cells st
R837 for 24 hr (I).
ImBecause Slc15a4/ mice showed the selective impairment of
IgG2a and IgG2c, but not IgG1 production (Figures 1A and 1B
and S1A and S1B), and the TLR7-dependent g2a GLT induction
was absolutely dependent on IFNAR (Figure S2B), we evaluated
Torin 1’s effects on g2a GLT induction in the context of the IFN-a
response. The IFN-a-dependent g2a GLT induction was signifi-
cantly but not completely inhibited by Torin 1 in WT B cells (Fig-
ure 7A), indicating that it is mediated by both mTOR-dependent
and -independent mechanisms. In Slc15a4/ B cells, and the
involvement of g2a GLT was slightly increased by IFN-a, but
Torin 1 did not inhibit this IFN-a-dependent g2a GLT induction
(Figures 7A and S6), suggesting that IFN-a rescued only the
mTOR-independent g2a GLT induction in these cells. This
finding also indicates that the mTOR-dependent g2a GLT induc-
tion in WT B cells was severely impaired in Slc15a4/ B cells.
The IFN-a-dependent Stat1 phosphorylation was not affected
by mTOR inhibition (Figure S2D), indicating that mTOR is not
involved in the IFNAR-mediated Stat1 phosphorylation events.
Although Torin 1 inhibited the g1 GLT induction (Figure 7B),
this g1 GLT appeared to be independent of IFN-a and
SLC15A4, since it was induced in Ifnar1/ or Slc15a4/ B cells
by R837 (Figure S2B), and exogenously added IFNa did not in-
crease the g1 GLT (Figures 7B and S6). Thus, g2a GLT and g1
GLT are differentially regulated with respect to the mTOR- and
IFN-a-dependency and the involvement of SLC15A4. We finally
confirmed the functional importance of mTOR pathway in B cell-
intrinsic TLR7 and TLR9 responses. Torin 1 efficiently inhibited
the TLR7-dependent IFN-I production (Figure 7C). TNF-a
production was less affected by the treatment with Torin 1
(Figure 7C). Similar results were obtained when B cells were
stimulated with CpG-ODN (Figure 7C). Collectively, our data
demonstrate that SLC15A4 is critical for the TLR-triggered path-
ogenic antibody production that occurs through the IRF7-IFN-I
regulatory circuit and the subsequent IFN-I response. This circuit
requires mTOR activation, which is accomplished by the
SLC15A4-dependent regulation of lysosomal conditions.
DISCUSSION
SLC15A4 is known to play a critical role in regulating the TLR7-
and TLR9-dependent IFN-I productions in pDCs and to be
involved in the pathogenesis of colitis and lupus-like diseases
(Baccala et al., 2013; Sasawatari et al., 2011). However, the mo-
lecular mechanism underlying SLC15A4’s involvement in these
TLR-dependent responses and disease has been poorly stud-
ied. We here demonstrated that SLC15A4 is critical for TLR-trig-
gered B cell functions, including proliferation, activation, andction and Subsequent IRF7 Expression
in HEK293T cells was detected by immunoblot (A) or visualized by confocal
ri-DAP for 24 hr, and the induced luciferase was quantified.
n SLC15A4 were stimulated with Tri-DAP for 24 hr, and the NF-kB activity was
ells. (E) WT or the E465Kmutant was reconstituted in Slc15a4/HSC-derived
antitative RT-PCR analysis of Ifnb1 or Il12b transcripts in WT- or E465K-re-
ults are representative of three independent experiments. (G) WT- or E465K-
tokines were measured by ELISA. **p < 0.01.
imulated with R837 for 1 hr (H), and Irf7 transcripts in the B cells stimulated with
munity 41, 375–388, September 18, 2014 ª2014 Elsevier Inc. 383
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Figure 5. Lysosomal Histidine and pH Are Controlled by SLC15A4 to Optimize Lysosomal Activity
(A) Deproteinized B cell extracts were separated, and histidine amount was analyzed by HPLC.
(B) Lysosomal-rich fractions (#4 and 5) from B cells were subjected to LC-MS/MS analysis, and the amino acid concentration was measured. Results are
representative of three independent experiments.
(C) Acidification of lysosomes upon TLR7 stimulation in B cells. WT or Slc15a4/ B cells labeled with LysoSensor were stimulated with R837 for the indicated
periods, and the fluorescence was analyzed by flow cytometry.
(D) WT or Slc15a4/ B cells or bone-marrow-derived DCs were incubated with FITC-conjugated CL264 (TLR7 ligand) for the indicated periods, and mean
fluorescence intensity (MFI) was analyzed by flow cytometry. Results are representative of three independent experiments.
(E) Amino acid-starved WT B cells were treated with histidine, and lysosomal acidification was analyzed. Results are representative of three independent
experiments. See also Figure S4.
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Figure 6. Altered Lysosomal Conditions in
SLC15A4-Deficient Mice
(A) Whole-cell lysates from WT or Slc15a4/ B
cells stimulated with IFN-a (500 U/ml) were
analyzed by immunoblotting; results are repre-
sentative of three independent experiments.
(B) Relative immunoblot intensities of phospho-
4EBP1 in TLR-stimulated B cells (Figure S5A) were
quantified and graphed.
(C) Subcellular distribution of SLC15A4 andmTOR
in HEK293T cells was visualized by confocal mi-
croscopy. Scale bar represents 5 mm.
(D) Cell homogenates from naive WT or
Slc15a4/ B cells (left) were separated and
mTOR and its regulatory elements in each fraction
were examined by immunoblotting. Immunoblot
band intensities of the indicated molecules were
quantified as described in Experimental Pro-
cedures (right). See also Figure S5.
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SLC15A4 Links mTOR and IRF7-IFN-I CircuitIFN-I production. SLC15A4 was required for the production of
IgG2a and IgG2c pathogenic antibodies in a B cell-intrinsic
manner, and the loss of SLC15A4 in B cells ameliorated the pro-
duction of IgG2a and IgG2c autoantibodies, such as anti-snRNP
and anti-DNA antibodies in mouse lupus models. We also
showed that SLC15A4 is pivotal for the establishment of the
IRF7-IFN-I regulatory circuit, a ‘‘feed-forward’’ loop for high
IFN production (Honda et al., 2006). Although the pathogenic
conditions of this multifactorial disorder cannot be explained
by a single molecule in a sole cell subset, our results demon-
strate that SLC15A4 plays a key role in integrating the functions
of these risk factors into a sequential process that promotes the
autoantibody production in B cells.
It is well established that IFN-I is crucial for antiviral immunity
and inflammation (Reizis et al., 2011). The mechanisms that
regulate IFN-I’s production in pDCs have been extensively inves-
tigated, and much is known about the TLR-dependent IFN-I
response. Our present findings establish that SLC15A4 plays a
critical role in IRF7-IFN-I circuit completion by promoting the
mTOR activity. SLC15A4 appears to have at least two differentImmunity 41, 375–388, Sesites of action in executing this function:
TLR7- and TLR9-proximal signaling
events and an IFNAR-distal signaling
event. Given that a lack of SLC15A4
impaired TNF-a, IL-6, and IFN-b produc-
tions in the early stages of the TLR7-
and TLR9-stimulation responses, it is
likely that both the NF-kB-dependent
and IRF-dependent pathways down-
stream of these TLRs are SLC15A4-
dependent. Because the basal mTOR
phosphorylation was also affected by
the SLC15A4 loss, we currently think
that the SLC15A4-mediated mainte-
nance of lysosomal conditions, including
the amino acid balance and acidity, might
be necessary to assure efficient TLR7-
and TLR9-proximal signaling. In addition,
the SLC15A4-contributed control of lyso-somal pH and the resultant efficient cathepsin activation also
seem to be important for initiating the TLR response.
Regarding the IFNAR-distal signaling event requiring
SLC15A4, IFN-I is known to activate the IRS-PI3K-Akt-mTOR
axis that leads to IRF7 activation (Lekmine et al., 2003) by
engaging IFNAR. Our results indicated that SLC15A4 is required
for the IFN-I-induced activation of the mTOR pathway and the
subsequent release of translational repression through 4E-BP1
phosphorylation, which results in the upregulation of IRF7 pro-
teins. The finding that IFNAR-downstream signaling events
such as Stat1 and Akt phosphorylation still occurred in IFN-
treated Slc15a4/ B cells indicates that SLC15A4’s regulation
of mTOR activity is exerted in the proximity of lysosomes. Taken
together, both the IFNAR-Stat1 axis and the IFNAR-mTOR-IRF7
axis are necessary to establish the IRF7-IFN-I regulatory circuit,
and the latter axis is dependent on SLC15A4.
Many central cellular events, including cell-cycle control, cell
growth, apoptosis, transcription, and translation, are regulated
by mTOR. The mTOR complex 1 senses conditions such as
the cellular metabolic state and amino acid content in theptember 18, 2014 ª2014 Elsevier Inc. 385
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Figure 7. mTOR Signaling Is Necessary for
g2a GLT Expression
(A) Quantitative RT-PCR analysis of g2a GLT in B
cells treated with indicated reagents for 48 hr. The
g2a GLT expression was normalized to that of
Hprt. Bars represent the average of triplicates and
SD. ***p < 0.001, n.s. not significant.
(B) RT-PCR analysis of g2a GLT and g1 GLT in WT
or Slc15a4/ B cells treated with indicated re-
agents. The Hprt gene was used as a control.
(C) Quantitative RT-PCR analysis of Tnf and Ifnb1
in TLR-stimulated B cells. Data are representative
of three independent experiments. See also
Figure S6.
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SLC15A4 Links mTOR and IRF7-IFN-I Circuitlysosome (Settembre et al., 2013; Zoncu et al., 2011b). Although
the precise mechanism that activates the mTOR pathway is still
largely unknown, our data using the SLC15A4 E465K mutant
indicate that the proper flow of particular amino acids or protons
from lysosomes into the cytosol, and the control of amino acid
and proton concentrations within lysosomes might be impor-
tant for mTOR activity and for efficient immune responses.
Lysosomal amino acids are known to activate mTORC1, and
v-ATPase-mediated amino acid sensing is necessary for the
translocation of the mTOR complex to the lysosomal surface
(Zoncu et al., 2011a). Although more work is needed to verify
the detailed mechanism of SLC15A4’s action in the context of
TLRs and mTOR signals, our observations highlight the impor-
tance of rigorous control of the lysosomal environment in inflam-
matory responses and disease pathogenesis. The lysosomal
environment includes its amino-acid and ion contents, which
are strongly affected by SLC15A4 and other lysosome-localized
transporters.
Regarding the mechanisms by which the SLC15A4-depen-
dent regulation of the lysosomal state enables the maximal effi-
ciency of the mTOR function, there are at least two possibilities,
which are not mutually exclusive. The first is that SLC15A4 af-
fects mTOR activity through v-ATPase’s function. The silencing
of v-ATPase subunits inhibits mTORC1’s lysosomal localization
and activation, indicating that v-ATPase has a key role in this
pathway (Zoncu et al., 2011a). Our findings that SLC15A4 loss
caused impaired lysosomal acidification and a change in the ba-
filomycin A1 sensitivity of v-ATPase suggest that v-ATPase is
functionally and/or conformationally altered in the absence of
SLC15A4. Since v-ATPase has a complex and highly organized
structure and is regulated by a reversible dissociation mecha-
nism that involves the breaking and reforming of protein-protein
interactions at the interface of the V1-ATPase and V0-proton386 Immunity 41, 375–388, September 18, 2014 ª2014 Elsevier Inc.channel domains, it is conceivable that
disorder of the lysosomal environment in
the absence of Slc15a4/ affects the
integrity of the v-ATPase complex (Zoncu
et al., 2011a). Thus, it is possible that
SLC15A4 supports the v-ATPase-depen-
dent mTORC1 activation. The idea that
accumulated histidine due to the lack of
SLC15A4 inhibits mTORC1 activity is
seemingly paradoxical to the current
view that a build-up of amino acids withinthe lysosomal lumen is required for mTORC1 activation. Howev-
er, the excess accumulation of histidine, a unique amino acid
with buffering capacity, might exert adverse pH-related effects
in a closed vesicular space. Because v-ATPase’s activity de-
pends on the presence of a pH gradient (Sakai et al., 2006), his-
tidine’s buffering effect might also disturb v-ATPase’s function at
the lysosomes. Although how SLC15A4 is needed for the func-
tional integrity of the mTOR complex and probably of the v-
ATPase at the lysosomes needs to be clarified, our finding that
there is an optimal range of histidine concentrations for control-
ling the lysosomal pH supports the above notion. The second
possibility is that SLC15A4’s transporter activity-independent
scaffolding or adaptor function affects the lysosomes’ biogen-
esis or integrity. Although our data using the SLC15A4 E465K
mutant support the first possibility, the second cannot be
formally excluded. Further investigation is necessary to under-
stand the precise mechanisms by which SLC15A4 regulates
the lysosome-dependent signaling events.
In summary, our study has revealed that SLC15A4 plays a
fundamental role in establishing the TLR-triggered IRF7-IFN-I
circuit. In this process, SLC15A4 mediates the activation of the
mTOR pathway downstream of IFNAR, by controlling lysosomal
conditions. Our findings indicate that SLC15A4 is an attractive
therapeutic target for autoimmune diseases associated with
autoantibody production.
EXPERIMENTAL PROCEDURES
Mice and Reagents
Slc15a4-deficient mice were generated as previously described (Sasawatari
et al., 2011). B cell-deficient mMT (Ighm/) mice were from S. Takaki (National
Center for Global Health &Medicine; NCGM), and Irf7/micewere from T. Ta-
niguchi (The University of Tokyo). Ifnar1/ mice were purchased from the
Jackson Laboratory. All animal experiments were approved by the Animal
Immunity
SLC15A4 Links mTOR and IRF7-IFN-I CircuitCare and Use Committee of the National Center for Global Health and Medi-
cine (NCGM) Research Institute (permit number: 14054), and conducted in
accordance with institutional procedures. R837 (Imiquimod), R848 (Resiqui-
mod), and E. coli LPS were purchased from Sigma; CpG-1668 from Hokkaido
System Science, the synthetic lipopeptide Pam3CSK4 was from InvivoGen.
Preparation of B Cells
Splenic B cells from naive mice were separated by CD43 microbeads (Miltenyi
Biotec) according to themanufacturer’s instructions. B cell purity was routinely
confirmed by flow cytometry (see Figure S7).
Gene-Expression Assays
cDNA was prepared from B cells or DCs and quantitative RT-PCR was con-
ducted with specific primers (see Table S1). Details are included in the Supple-
mental Experimental Procedures.
Flow Cytometry
Single-cell suspensions were prepared from the peripheral blood, spleen, and
bone marrow of mice, and red blood cells were lysed. The cells were stained
with the indicated monoclonal antibodies and analyzed by flow cytometry us-
ing a BD FACSCalibur (BD Biosciences).
Measurement of Immunoglobulins and Antibody Responses In Vivo
Immunoglobulin levels measured by ELISA using isotype-specific antibodies
purchased from Southern Biotech. Details are included in the Supplemental
Experimental Procedures.
Separation of Intracellular Vesicles and of Cytosolic or Nuclear
Fractions and Immunoassays
Intracellular vesicles were fractionated by suspending cells in extraction buffer
(50 mM HEPES- OH pH 7.5, 78 mM KCl, 4 mM MgCl2, 8.4 mM CaCl2, 10 mM
EGTA, 250 mM Sucrose, 1x Halt Protease Inhibitor, and 13 Halt Phosphatase
Inhibitor) and homogenized by shear force using a 29 gauge syringe. The cell
extract was fractionated by 5%–30%Opti-prep (Sigma) gradient ultracentrifu-
gation at 130,000 3 g for 4 hr. The fractionated vesicular proteins were sepa-
rated by 4%–20% SDS-PAGE, confirmed by immunoblotting, and used for
LC-MS/MS analysis. To separate cytosolic and nuclear fractions, we lysed B
cells with extraction buffer for 10 min and centrifuged them at 1,000 3 g for
5 min. The pellet was rinsed once with extraction buffer to remove leftover
cytosol and used as the nuclear fraction. Details on the fractionation methods
and the antibodies used for immunoblotting are provided in the Supplemental
Experimental Procedures.
Quantification of Amino Acids in B Cells
The histidine concentration in WT or Slc15a4/ B cells was measured by
HPLC using the amino acid derivatization method with NBD-F. To measure
the lysosomal amino acid concentration, we subjected the lysosomal fractions
from WT or Slc15a4/ B cells to LC-MS/MS analysis. Further details on the
amino acid quantification are provided in the Supplemental Experimental
Procedures.
Analysis of Autoimmune Disease
For long-term studies of autoantibody production, WT or Slc15a4/mice on a
BALB/c background received a single injection of 500 ml of TMPD, and the dis-
ease progression wasmonitored for over 20weeks. Further details on the anal-
ysis of the autoimmunemodels are provided in the Supplemental Experimental
Procedures.
Statistics
The statistical significance of differences in the mean ± SD of cytokines
released by cells of various groups was calculated with Student’s two-tailed
t test. p values less than 0.05 were considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.immuni.2014.08.011.ImAUTHOR CONTRIBUTIONS
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